Impact ledger
Eli Lilly and Company (LLY)
37 events mapped to this ticker since 2026-06-12.
Assumption changes
| Date | Assumption | Direction | Magnitude | Conf. |
|---|---|---|---|---|
| 2026-07-13 | revenue | Bullish | 85000000000.00 | 1.00 |
| 2026-06-17 | revenue | Bullish | — | 0.90 |
| 2026-06-12 | share_count | Bullish | — | 0.70 |
| 2026-06-12 | net_debt | Bullish | — | 0.70 |
| 2026-06-12 | revenue | Bullish | — | 0.70 |
Event impact log
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-07-16 | Event | Similar to Merck, strong demand signals in immunology and oncology, as evidenced by J&J's performance, could suggest a favorable market environment for other large-cap pharmaceutical companies with exposure to these therapeutic areas. | watch | 1-3m | 0.30 |
| 2026-07-13 | Event | Increased sales volume and pricing power for Mounjaro/Zepbound, leading to higher revenue and profitability. | Bullish | 1-5y | 0.90 |
| 2026-07-11 | Event | Investor sentiment and competitive landscape analysis. NVO's struggles might highlight LLY's relative strength or market leadership in the GLP-1 space, potentially attracting capital flows. | Bullish | 1-3m | 0.60 |
| 2026-07-05 | Event | As a leading GLP-1 drug manufacturer, increased and reliable cold-chain logistics capacity from UPS directly benefits Eli Lilly by ensuring efficient and safe distribution of its temperature-sensitive products, potentially expanding market reach and reducing supply chain risks. | Bullish | 1-3m | 0.50 |
| 2026-06-30 | Event | Potential acquirer or target in the 'merger mania' given its large market capitalization and pipeline needs. Could benefit from acquiring late-stage assets to mitigate patent cliff risks or be acquired for its strong pipeline. | watch | 3-12m | 0.60 |
| 2026-06-30 | Event | Direct M&A participant; potential acquirer of late-stage biotech assets to offset future patent expirations and expand into high-growth therapeutic areas like rare diseases. | watch | 1-5y | 0.70 |
| 2026-06-30 | Event | Indirect competitive pressure in the broader dermatology/psoriasis market, particularly for biologics. | watch | 3-12m | 0.20 |
| 2026-06-30 | Event | Strategic acquisitions to complement existing strong pipeline and expand into new therapeutic areas, particularly in rare diseases, potentially leading to increased R&D spend and future revenue. | mixed | 1-5y | 0.60 |
| 2026-06-26 | Event | J&J's strategic pivot towards biologics could lead to increased R&D and market entry in therapeutic areas where Eli Lilly has a strong presence, potentially affecting future growth. | watch | 3-12m | 0.30 |
| 2026-06-25 | Event | Direct acquisition of new assets and intellectual property, potential for future revenue streams from Centessa's pipeline, integration costs, and dilution from share issuance or cash outflow. | mixed | 1-5y | 0.60 |
| 2026-06-25 | Event | The repayment of Centessa's loan by Eli Lilly, as part of the acquisition, simplifies Centessa's balance sheet and removes a specific debt obligation. This is a minor positive as it streamlines the integration process and removes a small liability from the acquired entity, which is now part of LLY's | Bullish | 1-3m | 0.20 |
| 2026-06-24 | Event | Similar to Biogen, potential future competition or validation of the neurodegenerative disease market. Lilly is also a major player in neurological disorders and drug development. | watch | 1-5y | 0.15 |
| 2026-06-23 | Event | Increased competition in the I&I therapeutic area, potential for talent migration, and a benchmark for investor sentiment towards innovative biotech. | watch | 1-3m | 0.20 |
| 2026-06-23 | Event | Acquisition of potentially valuable R&D assets at a favorable price through bankruptcy proceedings, enhancing pipeline. | Bullish | 1-3m | 0.60 |
| 2026-06-23 | Event | Acquisition of specific assets from a distressed company, potentially at a favorable valuation, could enhance pipeline or technology portfolio. | Bullish | 1-3m | 0.30 |
| 2026-06-23 | Event | Heightened competition in the immunology space, particularly for atopic dermatitis (eczema) where Lilly has Lebrikizumab. AbbVie's strengthened pipeline could impact future market share dynamics. | watch | 1-3m | 0.20 |
| 2026-06-23 | Event | Similar to other large pharmaceutical companies, Eli Lilly could be a potential partner or acquirer seeking to expand its presence in metabolic diseases or liver conditions, given the high market potential of MASH. | watch | 3-12m | 0.20 |
| 2026-06-23 | Event | Potential for increased M&A competition and higher valuations for immunology assets, impacting future strategic options. | watch | 1-3m | 0.20 |
| 2026-06-23 | Event | Increased competitive pressure in immunology market, potential for other M&A activity in the sector. | watch | 3-12m | 0.20 |
| 2026-06-23 | Event | Potential for increased competitive intensity in the immunology space, particularly in atopic dermatitis where Lilly has significant market presence (e.g., Olumiant, Lebrikizumab). | watch | 3-12m | 0.30 |
| 2026-06-23 | Event | Potential for increased competitive pressure in the broader biopharmaceutical market, particularly in areas where AbbVie and Lilly's pipelines might overlap or compete for R&D talent. | watch | 3-12m | 0.20 |
| 2026-06-22 | Event | Potential competitive pressure in the antidepressant market. Eli Lilly has a history and current presence in neuroscience and psychiatric disorders. | watch | 3-12m | 0.20 |
| 2026-06-22 | Event | Increased competitive landscape in immunology, potentially affecting the long-term outlook for Lilly's immunology pipeline or existing products. | watch | 1-3m | 0.20 |
| 2026-06-22 | Event | Increased competitive pressure in the immunology market, potential for other large pharma companies to seek similar acquisitions. | watch | 1-3m | 0.30 |
| 2026-06-17 | Event | Potential shift in competitive landscape for certain therapeutic areas or manufacturing capabilities. | watch | 1-5y | 0.10 |
| 2026-06-17 | Event | Similar to Merck, Eli Lilly has a strong oncology focus. Positive results from Verastem could signal a new competitive threat or an attractive M&A opportunity in the long term. | watch | 3-12m | 0.20 |
| 2026-06-17 | Event | General competitive landscape shift in oncology, particularly for difficult-to-treat cancers, potentially impacting R&D focus or market dynamics. | watch | 3-12m | 0.15 |
| 2026-06-17 | Event | Increased market size and adoption for GLP-1 drugs, particularly with potential oral formulations, directly boosts sales of their leading GLP-1 products. | Bullish | 1-5y | 0.90 |
| 2026-06-17 | Event | Direct increase in market share and sales volume from leading GLP-1 products (e.g., Mounjaro, Zepbound) and potential future oral formulations. Continued insurance coverage expansion directly boosts patient access and prescription rates. | Bullish | 1-5y | 0.90 |
| 2026-06-16 | Event | Potential indirect impact on investor sentiment for companies with similar pipeline assets or development strategies. | watch | 3-12m | 0.20 |
| 2026-06-15 | Event | Indirect competitive pressure in the inflammatory bowel disease (IBD) market, as SPY002 could become a significant competitor to existing or pipeline IBD treatments. | watch | 1-3m | 0.20 |
| 2026-06-15 | Event | Potential indirect impact on partnership strategy and future collaboration opportunities in neuroscience. | watch | 1-3m | 0.10 |
| 2026-06-15 | Event | Potential long-term competitive threat in the Type 2 Diabetes market, though very early stage. | watch | 1-5y | 0.10 |
| 2026-06-15 | Event | Indirect competitive pressure. Eli Lilly has a presence in immunology and IBD. SPY002's positive data could signal a new effective treatment, potentially impacting the competitive landscape for Lilly's current or future IBD assets. | watch | 1-3m | 0.20 |
| 2026-06-15 | Event | General competitive pressure in the oncology market, particularly for companies with significant R&D investments in hematological malignancies. | watch | 1-5y | 0.10 |
| 2026-06-12 | Event | Acquisition of Centessa Pharmaceuticals' pipeline assets, potentially enhancing future revenue streams and mitigating patent expiry risks. | Bullish | 1-5y | 0.60 |
| 2026-06-12 | Event | Potential future competition in the GLP-1 market. While VKTX is small, a successful VK2735 could erode LLY's long-term market share or pricing power in the obesity/diabetes space. | watch | 3-12m | 0.40 |
This ledger is regenerated from Market Ontology's public event pipeline. For live alerts on new assumption changes for LLY, start a trial or view the LLY entity page.